10.3.00: UBS Warburg Global Life Sciences Conference 2000 Issue
Eight leading analysts and top management from eighty-two sector firms examine the Healthcare sector in this special 288-page UBS Warburg Global Life Sciences Conference 2000 issue from The Wall Street Transcript.
  1. Life Sciences - In an in-depth (3,300 words) Analyst Interview, Geoffrey Harris, Global Head of Healthcare Research at UBS Warburg, examines the outlook for the sector, including healthcare stocks, new life sciences devices, and shares specific stock recommendations.
  2. European Pharmaceutical Companies - In an in-depth (3,900 words) Analyst Interview, David Beadle, Director of Pharmaceutical Research at UBS Warburg, examines the outlook for the sector, including European pharmaceutical companies, Medicare drug benefit, and shares specific stock recommendations.
  3. Biotechnology - In an in-depth (2,900 words) Analyst Interview, Ross Taylor, Director and Equity Analyst at UBS Warburg, examines the outlook for the sector, including macro trends, screening workstation, and shares specific stock recommendations.
  4. Life Sciences Technology - In an in-depth (1,600 words) Analyst Interview, Vivek Khanna, Associate Director at UBS Warburg, examines the outlook for the sector, including genomics, drug discovery process, and shares specific stock recommendations.
  5. Diagnostic Products & Services - In an in-depth (1,700 words) Analyst Interview, Ricky Goldwasser, Director and Equity Analyst at UBS Warburg, examines the outlook for the sector, including industry trends, diagnostic testing, and shares specific stock recommendations.
  6. Vision Care Industry - In an in-depth (2,000 words) Analyst Interview, Rebecca Irwin, Associate Director at UBS Warburg, examines the outlook for the sector, including laser vision front, rate of adoption, and shares specific stock recommendations.
  7. European Biotechnology Companies - In an in-depth (3,300 words) Analyst Interview, Karl Keegan, Analyst at UBS Warburg, examines the outlook for the sector, including product-based companies, European biotechnology stocks, and shares specific stock recommendations.
  8. Biomaterials - In an in-depth (1,400 words) Analyst Interview, Jason Wittes, Equity Research Analyst covering the medical technology industry within the Healthcare Research Group at UBS Warburg, examines the outlook for the sector, including ENDOcare, Varian Medical Systems, and shares specific stock recommendations.
  9. CEO interviews (average 2,500 words). Top management of eighty-two sector firms examine the outlook for their firm and the sector. Firms include:
    Abgenix, ADAC Laboratories, Albany Molecular Research, Amylin Pharmaceuticals, Antigenics, Aronex Pharmaceuticals, Aspect Medical Systems, Axis-Shield, Beckman Coulter, Biocompatibles International, Caliper Technologies, Cambridge Antibody Technology Group, Cephalon, Cepheid, Chromagen, ChromaVision Medical Systems, Collateral Therapeutics, Conceptus, Connetics, Corixa, C.R. Bard, CryoLife, CYTOGEN, DENTSPLY International, Digene, Digirad, Eisai, ENDOcare, Enzo Biochem, EXACT Laboratories, Exelixis, Genomic Solutions, Genzyme Transgenics, Haemonetics, Human Genome Sciences, Hyseq, ILEX Oncology, INAMED, Incyte Genomics, Infectio Diagnostics, Integra LifeSciences Holdings, InterMune Pharmaceuticals, Intuitive Surgical, Invacare, Invitrogen, Laboratory Corporation of America Holdings, LaserVision Centers, Luminex, Medisys, Metabolex, Molecular Devices, Nabi, Nanogen, Neose Technologies, Pharmaceutical Product Development, PHASE1-Molecular Toxicology, Phylos, Promega, QIAGEN N.V., Quantum Dot, RITA Medical Systems, SangStat Medical, SciClone Pharmaceuticals, Sepracor, Sequenom, Sonic Innovations, SonoSite, STAAR Surgical Company, Stericycle, Straumann Holding AG, Structural GenomiX, Sybron International, Symyx Technologies, Syrrx, Targeted Genetics, ThermoGenesis, Trimeris, Tripos, V.I. Technologies, Varian, ViroLogic, Visible Genetics
    10. ORDER THIS REPORT NOW! ONLY $175
    The report will be mailed first class. For fedex delivery, specify in the report details section and either include your fedex number or we will add $15 delivery charge. All sales are final.  Questions, call (212) 952-7433, or email us
    For immediate access online - click here to gain a password.
     
    Report details:  
    Your Name:  
    		 Company: 
    Address: 
    		 City: 
    State/Province:
    		 ZIP/Postal Code:
          		 Country:
    Phone:
    		 E-Mail:

    BILLING INFORMATION
    Credit Card
    		 Expiration Month/Year:
    Credit Card Number: 
     

     This Issue costs $175 - and is non-returnable.   

    The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

     

Investors and Industry Execs.

The Wall Street Transcript has been used by investors and industry executives for 40 years as a unique tool for company and industry research.

TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. 

Money manager interviews provide the view from the buy-side.

CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.

Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher
HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE